An update: Health economics of managing multiple myeloma
Authors:
- 31 July 2006
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 42 (11) , 1684-1691
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Multiple Myeloma: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- Bortezomib for Myeloma — Much Ado about SomethingNew England Journal of Medicine, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Economic Evaluation of Zoledronic Acid Versus Pamidronate for the Prevention of Skeletal-Related Events in Metastatic Breast Cancer and Multiple MyelomaAmerican Journal of Clinical Oncology, 2005
- A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myelomaEuropean Journal of Cancer, 2004
- Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantationAnnals of Hematology, 2001
- Therapeutic Options in the Treatment of Multiple MyelomaPharmacoEconomics, 1999
- High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ ImmunoselectionJournal of Clinical Oncology, 1999
- Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin’s lymphoma patients after combination chemotherapy and G-CSFBone Marrow Transplantation, 1997